Literature DB >> 7855211

Effects of chronic phenylpropanolamine infusion and termination on body weight, food consumption and water consumption in rats.

S E Winders1, J C Amos, M R Wilson, P A Rushing, T Dykstra, M C Coday.   

Abstract

The present study determined the effect of chronic PPA infusion and withdrawal on weight regulation. Male Sprague-Dawley rats received PPA (0, 90 or 180 mg/kg) via miniosmotic pumps for 2 weeks. Body weight and food and water consumption were measured daily before, during, and for 2 weeks after PPA infusion. Additionally, body weight was measured once 6 weeks after the last day of drug administration. PPA infusion produced dose-dependent reductions in body weight and food consumption throughout drug administration. During the first week of PPA termination, food consumption returned to control levels; however, body weights of drug-treated animals remained below those of controls throughout the 6-week post-drug period. PPA depressed water intake during the first week of drug administration, but tolerance to this effect developed by the second week of administration. These results suggest chronic PPA infusion produces persistent appetite suppression and weight loss and that discontinuation of PPA does not result in hyperphagia or rapid weight gain. These findings may have clinical significance for the many individuals who wish to lose weight but have difficulty reducing intake without pharmacologic assistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855211     DOI: 10.1007/bf02249344

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

Review 1.  A review of the physiological bases of the anorexic action of phenylpropanolamine (d,1-norephedrine).

Authors:  P J Wellman
Journal:  Neurosci Biobehav Rev       Date:  1990       Impact factor: 8.989

2.  Contingent tolerance to the anorexigenic effects of amphetamine.

Authors:  P L Carlton; D L Wolgin
Journal:  Physiol Behav       Date:  1971-08

3.  Effects of nicotine on body weight in rats with access to "junk" foods.

Authors:  N E Grunberg; K A Popp; S E Winders
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Effects of amphetamine and phenylpropanolamine on food intake in rats with ventromedial hypothalamic or dorsolateral tegmental damage.

Authors:  P J Wellman; R H Peters
Journal:  Physiol Behav       Date:  1980-12

5.  Tolerance pattern of the anorexigenic action of amphetamines, fenfluramine, phenmetrazine and diethylpropion in rats.

Authors:  M N Ghosh; S Parvathy
Journal:  Br J Pharmacol       Date:  1976-08       Impact factor: 8.739

6.  [Pharmacokinetics of DL-norephedrine 14C in the rat].

Authors:  J F Thiercelin; C Jacquot; J R Rapin; Y Cohen
Journal:  Arch Int Pharmacodyn Ther       Date:  1976-03

7.  Thermogenic and anorectic effects of ephedrine and congeners in mice and rats.

Authors:  J R Arch; A T Ainsworth; M A Cawthorne
Journal:  Life Sci       Date:  1982-05-24       Impact factor: 5.037

8.  A comparison of the effects of phenylpropanolamine, d-amphetamine and d-norpseudoephedrine on open-field locomotion and food intake in the rat.

Authors:  M S Eisenberg; T J Maher; H I Silverman
Journal:  Appetite       Date:  1987-08       Impact factor: 3.868

9.  Effects of perifornical hypothalamic microinjections of phenylpropanolamine and amphetamine on latency to feed and mash intake in rats.

Authors:  P J Wellman; R Cockroft
Journal:  Pharmacol Biochem Behav       Date:  1990-02       Impact factor: 3.533

10.  Catecholaminergic mechanisms of the lateral hypothalamus: their role in the mediation of amphetamine anorexia.

Authors:  S F Leibowitz
Journal:  Brain Res       Date:  1975-11-21       Impact factor: 3.252

View more
  1 in total

1.  The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase in oxidative stress and appetite suppression.

Authors:  Yih-Shou Hsieh; Meng-Hsien Kuo; Pei-Ni Chen; Dong-Yih Kuo
Journal:  Neuromolecular Med       Date:  2012-11-20       Impact factor: 3.843

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.